MashUp Ventures Invests in Aslon

Aslon Co., Ltd. has secured investment from MashUp Ventures as the company continues to develop artificial intelligence (AI)-based medical software designed to support the early diagnosis and treatment planning of coronary artery disease in patients with stable angina.

Aslon’s core solution, AslonHeart-CAD, analyzes data from standard 12-lead electrocardiograms (ECG) to non-invasively assess a patient’s condition and assist clinicians in making more accurate diagnostic decisions.

Currently, coronary artery disease is often diagnosed only after patients begin experiencing severe symptoms such as chest pain. By that stage, many patients have already progressed to unstable angina or myocardial infarction, which can worsen patient outcomes and significantly increase the risk of emergency situations.

In contrast, AslonHeart-CAD aims to detect coronary artery stenosis early—during the stable angina phase—before the condition worsens. By enabling earlier intervention, the solution helps prevent progression to unstable angina or heart attacks, supports timely and optimal treatment decisions, improves patient quality of life, and enhances overall healthcare efficiency.

Based on its predictive analysis, AslonHeart-CAD also provides clinicians with comparative insights on the benefits and risks of pharmaceutical treatment versus invasive procedures such as stent implantation. This helps healthcare professionals make more personalized and informed treatment decisions for each patient.

A key competitive advantage of AslonHeart-CAD is its use of non-invasive and cost-effective 12-lead ECG data. Traditional diagnostic tools—such as cardiac CT or coronary angiography—are often expensive, invasive, and difficult to apply universally to all patients. Aslon addresses these limitations by enabling earlier detection using widely accessible screening methods.

Through AslonHeart-CAD, the company aims to establish a new paradigm for the early diagnosis and prevention of coronary artery disease, contributing to better health outcomes and quality of life for heart disease patients worldwide. Aslon plans to continue advancing research, development, and clinical validation to provide highly precise and reliable AI solutions, strengthening its position as a leader in cardiovascular healthcare technology.